twoXAR Pharmaceuticals is now ARIA Pharmaceuticals. Read More

science and pipeline

science and pipeline

Sound science starts with scientific stringency.

We believe that there is no replacement for scientific discipline when discovering and developing life-saving treatments. We differentiate ourselves from the traditional R&D approach by reducing the time from the discovery process to in vivo results by three years while maintaining the same level of scientific rigor. With our approach, we can start in vivo testing within a few months of initiating a program and with greater certainty that a potential therapy will succeed in early research, rather than the several years and low certainty expected with a traditional R&D approach. Accelerating drug discovery and development means that patients can potentially get new and much needed treatments sooner.

traditional versus Aria approach MOAs

PIPELINE

Using our scientific approach, Aria has developed a pipeline of promising treatments in over a dozen programs across a range of therapeutic areas. All of our candidates have shown sound safety and efficacy signals against some of today’s most challenging diseases. But that’s just the beginning. We have the power to apply our science in 1000+ complex diseases.

Aria Pipeline

PUBLICATIONS & POSTERS

Discovery & Preclinical Validation of Therapeutic Leads with Novel MOAs for CKD

Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty

Discovery & Preclinical Validation of Therapeutic Leads with Novel MOAs for CKD

Anjali Pandey, Isaac Hakim, Sana Mujahid, Aaron C. Daugherty

Preclinical identification and development of small molecule drug discovery leads with novel MOAs for non-alcoholic steatohepatitis (NASH)

Isaac Hakim, Sana Mujahid, Aaron C. Daugherty, Anjali Pandey, Timothy S. Heuer

NASH poster

Preclinical identification and development of small molecule drug discovery leads with novel MOAs for non-alcoholic steatohepatitis (NASH)

Isaac Hakim, Sana Mujahid, Aaron C. Daugherty, Anjali Pandey, Timothy S. Heuer

Computational discovery and preclinical validation of therapeutic leads with novel MOAs for hepatocellular carcinoma and pancreatic ductal adenocarcinoma

Isaac Hakim, Mei-Sze Chua, Wei Wei, Li Ma, Samuel So, Elizabeth Noblin, Sana Mujahid, Aaron C. Daugherty, and Timothy S. Heuer

pancreatic ductal adenocarcinoma

Computational discovery and preclinical validation of therapeutic leads with novel MOAs for hepatocellular carcinoma and pancreatic ductal adenocarcinoma

Isaac Hakim, Mei-Sze Chua, Wei Wei, Li Ma, Samuel So, Elizabeth Noblin, Sana Mujahid, Aaron C. Daugherty, and Timothy S. Heuer

Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)

Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer

Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)

Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer

Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)

Isaac Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer

EULAR SLE Poster

Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)

Isaac Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer